Source
|
Age
|
Thyroid disorder
|
Diagnosis
|
Durationa
|
Drug
|
Malignancy <5 yrs
|
Medical history
|
Pregnancy/Breast feeding
|
---|
Clinics
|
2 (2.3%)
|
3 (3.4%)
|
2 (2.3%)
|
11 (13%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
2 (2.3%)
|
Register
|
1 (1.7%)
|
2 (3.4%)
|
1 (1.7%)
|
2 (3.4%)
|
1 (1.7%)
|
0 (0%)
|
0 (0%)
|
0 (0%)
|
Internet
|
25 (15%)
|
0 (0%)
|
0 (0%)
|
24 (15%)
|
0 (0%)
|
1 (0.6%)
|
1 (0.6%)
|
1 (0.6%)
|
- a11 participants who registered with the DILT1D study team had a duration of T1D of between 20 and 24 months. This group were unable to enrol in the trial before they became ineligible.